Response to chemotherapy in juvenile myelomonocytic leukemia and its clinical implications for survival: A retrospective registry-based study of the Korean Pediatric Hematology-Oncology Group.

[1]  M. Rudelius,et al.  The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia , 2022, Virchows Archiv.

[2]  Sang Kyu Park,et al.  Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group , 2022, Bone Marrow Transplantation.

[3]  S. Rives,et al.  Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. , 2021, Blood advances.

[4]  C. Niemeyer,et al.  Current Treatment of Juvenile Myelomonocytic Leukemia , 2021, Journal of clinical medicine.

[5]  D. Sahoo,et al.  Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine , 2020, Pediatric hematology and oncology.

[6]  M. Loh,et al.  Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia , 2019, Pediatric blood & cancer.

[7]  C. Niemeyer,et al.  Juvenile myelomonocytic leukemia: who's the driver at the wheel? , 2019, Blood.

[8]  Ke Huang,et al.  Diagnosis and treatment of juvenile myelomonocytic leukemia , 2019, Hematology.

[9]  M. Loh,et al.  Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study , 2018, Pediatric blood & cancer.

[10]  F. Locatelli,et al.  Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia , 2018, Expert review of hematology.

[11]  A. Koc,et al.  Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients , 2017, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[12]  M. Loh,et al.  Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia , 2017, Nature Communications.

[13]  Melanie Boerries,et al.  RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia , 2017, Nature Communications.

[14]  A. Baruchel,et al.  Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.

[15]  T. Golub,et al.  The Genomic Landscape of Juvenile Myelomonocytic Leukemia , 2015, Nature Genetics.

[16]  Franco Locatelli,et al.  How I treat juvenile myelomonocytic leukemia. , 2015, Blood.

[17]  M. Loh,et al.  Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia , 2015, Haematologica.

[18]  M. Loh,et al.  Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation , 2014, Front. Pediatr..

[19]  Y. Nakazawa,et al.  Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia , 2014, Leukemia.

[20]  J. Wagner,et al.  Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. , 2010, Blood.

[21]  C. Plass,et al.  Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. , 2011, Blood.

[22]  M. Loh,et al.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. , 2009, Leukemia research.

[23]  A. Yoshimi,et al.  Correlation of Clinical Features With the Mutational Status of GM-CSF Signaling Pathway-Related Genes in Juvenile Myelomonocytic Leukemia , 2009, Pediatric Research.

[24]  C. Niemeyer,et al.  Non‐hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria , 2007, Pediatric blood & cancer.

[25]  E. Lanino,et al.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. , 2005, Blood.

[26]  H. Shin,et al.  Novel regimen for the treatment of juvenile myelomonocytic leukemia (JMML). , 2004, Leukemia research.

[27]  C. Stiller,et al.  Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population‐based study of incidence and survival , 2003, British journal of haematology.

[28]  J. Buckley,et al.  Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.